12:31 PM
 | 
Jul 14, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA panel backs approval of Amgen's Avastin biosimilar

FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 17-0 in favor of approving ABP 215 from Amgen Inc. (NASDAQ:AMGN). The product is a biosimilar of Avastin bevacizumab from the Genentech Inc. unit of

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >